PTO/SB/21 (01-03)

Approval for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number						
		Application Number	10/054,579			
TRANSMITTAL			Filing Date	Jan 22, 2002		
FORM		First Named Inventor	Turner			
(to be used for all correspondence after initial filing)		Art Unit	1652			
		Examiner Name	Monshipouri, Maryam			
Total Number of Pages in This Submission 5		Attorney Docket Number	LEX-0300-USA			
ENCLOSURES (check all that apply)						
Fee Trar	nsmittal Form		Drawing(s)		After Allowance Communication to Group	
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences		
X Amendment / Reply			Petition		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final			Petition to Convert to a Provisional Application		Proprietary Information	
Affidavits/declaration(s)			Power of Attorney, Revocation Change of Correspondence Addre		ess Status Letter	
Extension of Time Request			Terminal Disclaimer		X Other Enclosure(s) (please identify below):	
Express Abandonment Request		╽Ш	Request for Refund		Return Postcard	
Information Disclosure Statement			CD, Number of CD(s)			
Certified Copy of Priority Document(s) Remarks			ks			
Response to Missing Parts/ Incomplete Application			Customer # 24231			
Response to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm	Lexicon Genetics Incorporated					
or Individual	Lance K. Ishimoto Reg. No. 41,866					
Signature force K. Slomina by Davil N. J. Loly Res. No. 41,071						
Date	May 21, 2004					
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient						
l .	ss mail in an envelope addressed to 450, Alexandria, VA 22313-1450 on				May 21, 2004	
Typed or printed Michelle Klein						
Signature VIIII				Date	May 21, 2004	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. Washington, DC 20231.



FW/656

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Turner, Jr. and Mathur

Group Art Unit:

1652

Application No.:

10/054,579

Examiner:

M. Monshipouri

Filed:

01/22/2002

Atty. Docket No.: LEX-0300-USA

Title: Novel Human Kinases and Polynucleotides

Encoding the Same

AMENDMENT; AND RESPONSE TO OFFICE ACTION DATED FEBRUARY 23, 2004

Commissioner for Patents Alexandria, VA 22313

Sir:

The Applicants acknowledge the receipt of the Office Action ("the Action") mailed on February 23, 2004, which has been carefully reviewed and studied. The Examiner is respectfully requested to enter the following amendments. Reexamination and reconsideration of the application is requested in view of the following amendments and remarks. In order to facilitate the Examiner's evaluation of the application, Applicants have attempted to address the rejections in the Action in the same order in which they were originally raised.

A response to the Action is due on May 23, 2004, which falls on a Sunday and is therefore extended until Monday, May 24, 2004 under 37 C.F.R. § 1.7. The present response is thus timely filed, and Applicants believe no fees are due in connection with the present response. However, the Commissioner is authorized to charge any additionally required fees or credit any overpayment to Deposit Account No. 50-0892.